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ABSTRACT:
The canonical view of the origin of tumor lymphovascular emboli is that they usually 
originate  from  lymphovascular  invasion  as  part  of  a  multistep  metastatic  process. 
Recent experimental evidence has suggested that metastasis can occur earlier than 
previously thought and we found evidence that tumor emboli formation can result from 
the short-circuiting step of encircling lymphovasculogenesis. Experimentally, we used a 
xenograft of human inflammatory breast cancer (MARY-X), a model that exhibited florid 
tumor emboli, to generate tumoral spheroids in vitro. In observational studies, we chose 
human breast carcinoma cases where there appeared to be a possible transition of in 
situ carcinoma to lymphovascular emboli without intervening stromal invasion. These 
cases were studied by morphometry as well as IHC with tumor proliferation (Ki-67) and 
adhesion (E-cadherin) markers, myoepithelial (p63), as well as endothelial (podoplanin 
[D2-40], CD31, VEGFR-3, Prox-1) markers. Unlabelled spheroids coinjected with either 
GFP or RFP-human myoepithelial cells or murine embryonal fibroblasts (MEFs) gave 
rise to tumors which exhibited GFP/RFP immunoreactivity within the cells lining the 
emboli-containing lymphovascular channels. In vitro studies demonstrated that the 
tumoral  spheroids  induced  endothelial  differentiation  of  cocultured  myoepithelial 
cells and MEFs, measured by real time PCR and immunofluorescence. In humans, the 
in situ clusters exhibited similar proliferation, E-cadherin immunoreactivity and size as 
the tumor emboli (p =.5), suggesting the possibility that the latter originated from 
the  former.  The in situ clusters  exhibited  a  loss  (50%-100%)  of  p63  myoepithelial 
immunoreactivity but not E-cadherin epithelial immunoreactivity.  The tumor emboli 
were mainly present within lymphatic channels whose dual p63/CD31, p63/D2-40 and 
p63/VEGFR-3 and overall weak patterns of D2-40/CD31/VEGFR-3 immunoreactivities 
suggested  that  they  represented  immature  and  newly  created  vasculature  derived 
from  originally  myoepithelial-lined  ducts.  Collectively  both  experimental  as  well  as 
observational studies suggested the possibility that these breast cancer emboli resulted 
from  encircling  lymphovasculogenesis  rather  than  conventional  lymphovascular 
invasion.  132
INTRODUCTION
The  canonical  view  of  human  cancer  progression  is 
that in situ carcinoma progresses to invasive carcinoma 
which  become  lymphovascular  emboli  that  metastasize. 
It  is  widely  accepted  that  metastasis  is  a  late  event  in 
cancer progression. Recent studies in transgenic mice have 
observed that metastasis can occur earlier in tumor progres-
sion than previously thought [1]. Possible explanations for 
“early metastasis” include passive dissemination of tumor 
cells by iatrogenic mechanisms, synchronous or metachro-
nous  transformation  of  stem  or  progenitor  cells  present 
in diverse locations and the ability of in situ or incipient 
cancers to bypass many of the traditionally rate-limiting 
steps of the metastatic process which include stromal inva-
sion, angiogenesis, lymphangiogenesis, intravasation and 
extravasation [2-8]. 
Lymphovascular  invasion  (LVI),  lymphangiogenesis 
and vasculogenesis are all important steps in tumor metas-
tasis and these steps in themselves can occur through sev-
eral  different  mechanisms  [9-14].  One  such  mechanism 
is vasculogenic mimicry [15-21]. This type of mimicry is 
exhibited by several experimental models of tumor pro-
gression  whereby  tumor  cells  directly  differentiate  into 
vascular channels and bypass the reliance on conventional 
angiogenesis  [17-19].  Another  potential  mechanism  of 
bypassing  conventional  angiogenesis  is  the  recruitment 
of local or bone marrow-derived stem cells to participate 
in  vasculogenesis  [20]. Along  these  lines,  we  searched 
for evidence to suggest that some of the steps of human 
cancer progression could be side-stepped so that human 
cancers would be positioned to metastasize earlier in their 
natural history. The evidence that we found and present in 
this study suggests that the step of tumor emboli formation 
results from the short-circuiting step of encircling lympho-





Our  xenograft  model  of  human  inflammatory  breast 
cancer (MARY-X), a model that exhibited a nodular growth 
pattern  in  its  center  (Figure  1A),  LVI  at  its  periphery 
(Figure 1B) with involvement of adjacent dermal lymphat-
ics (Figure 1C) exhibited large numbers of spontaneous 
pulmonary metastases. The xenograft generated numerous 
tumoral spheroids in vitro. Unlabeled MARY-X tumoral 
spheroids (Figure 2A) coinjected with either GFP or RFP-
labeled human myoepithelial cells (HMS-1) (Figure 2B) or 
MEFs into nude mice gave rise to tumors which exhibited 
GFP or RFP fluorescence. Green or red fluorescence was 
observed within the emerging tumor nodules based on the 
coinjected GFP or RFP-labeled HMS-1 or MEFs. Interest-
ingly in the experiments involving the mixture of unlabeled 
spheroids with RFP-labeled HMS-1 or MEFs in GFP-trans-
genics, the tumor nodules initially exhibited a red fluores-
cence (Figure 2C) which over time gave rise to a hybrid 
yellow fluorescence (Figure 2D). On IHC examination of 
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Figure  1.  Histopathology  of 
MARY-X  (A)  MARY-X  exhibits  a 
centrally prominent nodular growth 
pattern. (B) Peripheral to the main 
mass,  a  tumor  embolus  within  an 
adjacent  lymphovascular  space  is 
observed. (C)   Florid LVI of overly-
ing dermal lymphatics is observed.
Figure 2. MARY-X spheroids with fluorescently labeled HMS-1/
MEFs (A) MARY-X gives rise to spheroids in vitro which consist of 
very tight aggregates of tumor cells in suspension culture.  (B) Ret-
roviral transfection and G418 clonal selection gives rise to HMS-1 
clones expressing strong RFP. (C) Coinjection of MARY-X spher-
oids with RFP-HMS-1 cells in GFP-transgenic nudes gives rise to 
tumors initially expressing red fluorescence. Identical results were 
observed when the spheroids were coinjected with RFP-MEFs. 
(D) Over time the red-fluorescing nodules (MARY-X spheroids + 
RFP-HMS-1) depicted previously expressed a hybrid yellow fluo-
rescence.
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the extirpated tumor nodules, circumferential GFP or RFP 
immunoreactivity was observed surrounding the tumor cell 
clusters (Figure 3A). Unlabeled MARY-X tumoral spher-
oids coinjected with either GFP or RFP-labeled HDFs gave 
rise to tumors which did not fluoresce. On IHC examina-
tion of the extirpated tumor nodules, no GFP or RFP encir-
cling immunoreactivity was observed.
These present studies are immunocytochemical stud-
ies and not fluorescence studies (Figure 3A; Figure 3B). 
Although  GFP  and  RFP  fluoresce  green  and  red  colors 
respectively when subjected to UV light, under white light 
they do not fluoresce. In analyzing the extirpated xeno-
grafts we used rabbit polyclonal antibodies to GFP and 
RFP and secondary goat anti-rabbit antibodies conjugated 
with DAB, giving a brown color at sites of GFP or RFP. 
The brown color demonstrated reflects the presence of GFP 
(Figure 3A; Figure 3B). The GFP immunoreactivity shows 
brown staining around the clusters of tumor cells, hence 
it shows encircling immunoreactivity (Figure 3A). In par-
ticular, the brown-colored cells appear to be lining a space 
which surrounds a clump of tumor cells (Figure 3B). When 
one looks carefully at this space, the presence of luminal 
erythrocytes (red blood cells) is noted suggesting that this 
space is indeed a lymphovascular space.
In vitro studies. 
Experiments  with  either  GFP-labeled  HMS-1  or 
GFP-labeled MEFs cocultured with unlabeled MARY-X 
spheroids in Matrigel revealed prominent chemotaxis and 
haplotaxis of the HMS-1 or MEFs toward the spheroids 
(Figure 4A) with near complete encircling of either of the 
former  cells  around  the  spheroids  by  72-96  hrs  (Figure 
4B). Antibodies against human-specific or murine-specific 
CD31 revealed expression of this molecule on the HMS-1 
or MEFs respectively after they had surrounded the spher-
oids (Figure 4C). The detection system utilized a Texas-
red conjugated secondary antibody which produced hybrid 
yellow fluorescence in the GFP-labeled HMS-1 or MEFs 
(Figure 4C). Both the HMS-1 cells and the MEFs were 
essentially  negative  for  CD31  immunoreactivity  when 
cultured in isolation or when they were not encircling the 
MARY-X spheroids (Figure 4C). 
The  vast  majority  of  individual  cells  outside  of  the 
spheroid  showed  only  green  fluorescence  (Figure  4C). 
Although rare outside cells showed red and yellow fluo-
rescence,  clearly  the  cells  that  encircled  the  spheroid 
showed much more intense yellow fluorescence. Therefore 
this data clearly showed the acquisition of CD31 immu-
noreactivity in the cells that have encircled the spheroid. 
Although it is possible that this yellow color was the result 
of a dual population of cells, one with green fluorescence 
only and the other exhibiting red (CD31) immunofluores-
Figure  3:  MARY-X  coinjection  immunocytochemical  studies   
(A) Immunocytochemical studies of an extirpated tumor coinjected 
with GFP-labeled MEFs reveals tumoral nodules surrounded by 
encircling GFP immunoreactivity. Identical results were observed 
when the spheroids were coinjected with GFP-HMS-1. (B) Higher 
magnification of these tumoral nodules reveals their location within 
a space containing GFP immunoreactivity in its lining and luminal 
erythrocytes (arrows).   
Figure 4. In vitro coculture fluorescent studies (A) Coculture 
experiment with Matrigel viewed with the Fluorescence Imaging 
Microscopy-Nikon Eclipse TE2000-U System revealed the GFP-
labeled MEFs migrating toward the unlabeled spheroids of MARY-
X. (B) Over the next 72-96 hr, the GFP-MEFs completely encircled 
the spheroids. (C) Applying a rat anti-mouse CD31 antibody fol-
lowed by a Texas red-conjugated rabbit anti-rat indicates hybrid 
yellow  CD31  expression  by  the  GFP-MEFs  spheroid-encircling 
cells. Isolated MEFs themselves were largely negative for CD31 
(mainly  green).  Fluorescent  patterns  were  similar  when  GFP-
HMS-1 were cocultured with the spheroids and a rat anti-human 
CD31 was used. 
Figure  5.  Real  time  PCR  for  endothelial 
growth factors and receptors. (A) Real time 
PCR  of  relative  mRNA  levels  of  the  VEGF 
family (VEGF-A, VEGF-B, VEGF-C, VEGF-D) 
for different breast carcinoma cell lines and the 
spheroids of MARY-X. Results depicted are a 
mean + standard deviation of 5 experiments. 
(B)  Real  time  PCR  of  relative  mRNA  levels 
of  the  VEGFR  family  (VEGFR-1,VEGFR-2, 
VEGFR-3),  CD31  and  podoplanin  over  time 
(hr) for HMS-1 cells cocultured in media with 
MARY-X  spheroids.  Results  depicted  are  a 
mean + standard deviation of 5 experiments.
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cence only, we feel that this alternative explanation is not 
likely because outside of the spheroid, the vast majority of 
cells exhibit green fluorescence and only rare numbers of 
cells exhibiting red and yellow immunofluorescence are 
observed. Therefore it is more likely that the GFP-labeled 
cells acquire CD31 immunoreactivity when they encircle 
the spheroid and change to a yellow color. A single popula-
tion of cells then emit both green fluorescence and acquire 
this red immunofluorescence producing a hybrid yellow 
color. 
MARY-X spheroids prior to coculture were harvested 
and compared to a series of common breast carcinoma cell 
lines with respect to mRNA transcript levels by real time 
PCR of the VEGF family of growth factors. The HMS-1 
myoepithelial cell line was used as control. The ER nega-
tive  lines  (MDA-MB-468,  MDA-MB-231)  exhibited 
higher levels of VEGF-C and VEGF-A expression respec-
tively than the ER positive lines (MCF-7, HTB20) (Figure 
5A). MARY-X spheroids also exhibited very high levels of 
VEGF-C and reasonably high levels of VEGF-D (Figure 
5A), compared to other line. 
Experiments  with  HMS-1  cocultured  with  unlabeled 
MARY-X spheroids in regular culture media revealed an 
interesting pattern of induction of gene expression in the 
HMS-1 cells. Members of the VEGFR family (VEGFR-1, 
VEGFR-2, VEGFR-3), CD31 and podoplanin all showed 
increased transcript levels over time of coculture by real 
time PCR. The most striking increase in transcripts was in 
VEGFR-3 and CD31 at 96 hr (Figure 5B). Coculture of 
HMS-1 with other breast carcinoma cell lines induced to 
grow as spheroids produced no appreciable increase in the 
transcripts (data not shown).   
Observational studies
The  relevant  clinicopathological  information  of  the 
selected  cases  and  age-  and  size-matched  controls  is 
Feature Cases Controls Significance
Breast appearance ---- ---- ----
             Redness 0/10 0/10 p=.5
             Edema 0/10 0/10 p=.5
             Nipple retraction 0/10 0/10 p=.5
Mammographic appearance ---- ---- ----
             Abnormal microcalcifications 9/10 8/10 p=.5
             Abnormal density 9/10 9/10 p=.5
Size (diameter)  1-5 cm 1-5 cm p=.5
Previous FNA 1/10 2/10 p=.1
Previous core biopsy 3/10 4/10 p=.1
Concurrent sentinel node procedure 4/10 6/10 p=.1
Subsequent sentinel node procedure 6/10 4/10 p=.1
Grade of DCIS ---- ---- ----
             Low 1/10 2/10 p=.5
             Intermediate 3/10 3/10 p=.5
             High 6/10 5/10 p=.5
Stromal invasion 0/10 0/10 p=.5
Lymphovascular invasion 10/10 0/10 p=.01
Paget’s disease of nipple 2/10 1/10 p=.5
Axillary lymph node status ---- ---- ----
             Positive sentinel node 7/10 1/10 p=.01
             Positive additional nodes 3/10 0/10 p=.01
Biomarker profile ---- ---- ----
             ER +, PR +, Her-2/neu - 3/10 3/10 p=.5
             ER +, PR -,  Her-2/neu - 1/10 2/10 p=.5
             ER -,  PR +, Her-2/neu - 1/10 0/10 p=.5
             ER-, PR -, Her-2/neu + 3/10 3/10 p=.5
             Triple negative 2/10 2/10 p=.5
Surgical procedure ---- ---- ----
             Lumpectomy 8/10 9/10 p=.5
             Mastectomy 2/10 1/10 p=.5
Table 1. Clinicopathologic features of the human cases exhibiting 
direct in situ - LVI without stromal invasion compared to age-
matched and size-matched controls.
Figure  6.  Histopathology  of  human  breast  car-
cinoma cases. (A) Classic DCIS (right) juxtaposed 
to  lymphovascular  invasion  (left)  with  no  interven-
ing stromal invasion. (B) Classic DCIS (upper right) 
with no intervening stromal invasion juxtaposed to a 
tumor embolus within a lymphatic space (lower left), 
the latter identified by D2-40 immunoreactivity. 
Figure 7. Immunocytochemistry of human breast 
carcinoma cases (A) Classic DCIS (upper right) and 
adjacent lymphovascular tumor embolus (lower left) 
exhibits E-cadherin immunoreactivity. (B) The lym-
phovascular tumor embolus in A (higher magnifica-
tion) exhibits E-cadherin immunoreactivity.  (C) DCIS 
transitioning  to  possible  LVI  exhibits  E-cadherin 
immunoreactivity. (D) DCIS exhibits Ki-67 immunore-
activity. (E) The lymphovascular tumor embolus (left) 
exhibits Ki-67 immunoreactivity. 
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depicted (Table 1). The 10 cases chosen for morphometric 
and immunocytochemical studies all showed prominent in 
situ carcinoma adjacent to florid LVI (Figure 6A; Figure 
6B) (Table 1). 
Exhaustive sectioning failed to reveal intervening stro-
mal invasion. The immediate question which was raised by 
these observations was whether the in situ carcinoma cells 
had gained access to the lymphovascular space through an 
alternate non-invasive mechanism. The in situ clusters in 
all of these cases exhibited no statistically significant dif-
ferences in E-cadherin membrane or Ki-67 nuclear prolif-
eration immunoreactivities compared to those exhibited by 
the tumor emboli within the lymphovascular channels (p 
= 0.5; p = 0.5) (Figure 7A; Figure 7B; Figure 7C; Figure 
7D; Figure 7E) (Table 2). The mean perimeter of the in situ 
clusters (1221 μ) did not differ significantly from that of the 
lymphovascular tumor emboli (1084 μ) (p=0.54) (Table 2) 
(Figure 8A; Figure 8B; Figure 8C). The in situ clusters dif-
fered only slightly in shape from the lymphovascular tumor 
emboli: the DCIS clusters tended to be round and smooth 
whereas the lymphatic tumor emboli were more oval and 
slightly irregular in shape. The elongation ratio of the in 
situ clusters was 0.85 ± .10 compared to the elongation 
ratio of the lymphatic tumor emboli which was 0.70 ± .2 
but this difference was only minimally significant (p=0.05) 
(Table 2).
These morphometric and immunocytochemical similar-
ities exhibited by the in situ clusters and the lymphovascu-
lar tumor emboli suggested that these structures were one 
and the same and remained intact during their in situ to LVI 
transition. Only 4/10 cases had a prior FNA or core biopsy. 
No FNA or core biopsy tract was present in any of the areas 
of the in situ -LVI transition. Although all 10 cases eventu-
ally had a sentinel lymph node biopsy, only the 4 cases with 
a prior FNA or core biopsy had the sentinel lymph node 
procedure performed at the time of the excisional biopsy. 
The absence then of any antecedent physical manipulations 
in the majority of cases excluded mechanical disruption or 
an iatrogenic mechanism as the cause of this in situ -LVI 
transition. The clinicopathological characteristics exhibited 
by the cases showing this in situ -LVI transition were not 
dissimilar from the control in situ except for a dispropor-
tionately high degree of axillary nodal metastasis in the 
former (p=.01) (Table 1).  
In these cases, DCIS exhibited overall fewer numbers of 
surrounding p63 positive myoepithelial cells than normal 
ducts in the same sections (p=.01) (Figure 9A; Figure 9B; 
Figure 9C) (Table 3). 
Tumor Clustera DCIS LVI t-test
         E-cadherinb 95±5% 93±6% p=0.5
         Ki-67c 23±4% 25±8% p=0.5
         Size (perimeter)d 1221μ±180 1084μ±160 p=0.1
         Shape (elongation ratio)e 0.85±.10 0.70±.05 p=.05
Table 2. Distribution of tumor marker immunoreactivity and 
morphometric values 
a 100 clusters of DCIS and tumor emboli were individually analyzed 
for the given immunoreactivity or morphometric measurement and 
expressed as Mean ± SD. Differences were analyzed with the Stu-
dent’s t-test. 
b E-cadherin immunoreactivity was measured as the percentage of 
tumor cells exhibiting membrane positivity.
c Ki-67 immunoreactivity was measured as the percentage of tumor 
cells exhibiting nuclear positivity.  
d Size was measured as the perimeter of the DCIS clusters or lym-
phovascular tumor emboli and analyzed  with ImageJ algorithms.
e Shape was measured as the elongation ratio (ratio of short to long 
axis) of the DCIS clusters or lymphovascular tumor emboli and 
analyzed with standard imaging algorithms. 
Immunoreactivitya 0%           ≤50%   >50% t-test
p63 in normal ductsb 0 0 100%
p63 in DCIS 4% 52% 44% p=.01
CD31 in normal vessels 0 0 100%
CD31 in LVI 75% 20% 5% p=.01
D2-40c in normal lymphatics 0 0 100%
D2-40 in LVI 55% 34% 11% p=.01
p63 in normal vessels/lymphatics 100% 0% 0%
p63 in LVI 97%  Occasional cells 0% p=.05
p63/CD31 in normal vessels 100% 0 0
p63/CD31 in LVI  95%  Occasional cells 0% p=.05
p63/D2-40 in normal lymphatics 100% 0 0
p63/D2-40 in LVI 97%  Occasional cells 0% p=.05
a A total of 100 ducts, lymphatics and blood vessels were separately counted. Immunoreactivity around these ducts and vessels is 
recorded as a percentage of circumferential immunoreactivity.
b Immunoreactivity for the designated marker(s) is recorded as percentage of 100 structures showing the indicated degree of circum-
ferential immunoreactivity.
c The distribution of two other lymphatic endothelial markers, nuclear Prox-1 and cytoplasmic/membrane VEGFR-3 was similar to 
D2-40 (p=0.1).
Table 3: Distribution of myoepithelial and endothelial immunoreactivity 
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In this analysis, we examined all types of vascular struc-
tures including lymphatics and blood vessels. Oftentimes it 
was difficult to distinguish lymphatics from blood vessels 
in routine sections. It was even difficult when using immu-
nocytochemical methods as most single antibodies are not 
that specific in distinguishing blood vessels from lymphat-
ics. In our hands we found that CD 31 was present in both 
blood vessels as well as lymphatics but that VEGFR-3, 
Prox-1 and podoplanin (D2-40) immunoreactivites were 
more specific for lymphatics. We used this combination 
of antibodies to support the conclusions of the study. Posi-
tive circumferential CD31 and D2-40 immunoreactivities 
meant immunoreactivities present along the lining circum-
ference of the vessel which was further semiquantitated as 
being less ≤ 50% or >50% (Table 3).
Four  adjacent  lymphovascular  populations  were  in 
evidence: blood vessels which were strongly CD31 posi-
tive and which were devoid of tumor emboli; lymphatics 
which  were  strongly  D2-40,  Prox-1  or  VEGFR-3  posi-
tive and which were devoid of tumor emboli; lymphatics 
which were either less circumferentially D2-40, Prox-1 or 
VEGFR-3 positive or negative and which contained tumor 
emboli and lymphatics which were either less circumfer-
entially CD31 positive or negative and which contained 
tumor emboli. There were differences in the the presence 
versus the absence and in the circumferential distribution 
of CD31 and D2-40, Prox-1 and VEGFR-3 immunoreac-
tivities within the normal vessels in the breast cancer sec-
tions compared to those vessels containing tumor emboli 
(p=.01), (p=.01) (Figure 9D; Figure 9E; Figure 9F) (Table 
3). To exclude subjectivity in perception or variations in 
immunocytochemical staining in different batch runs, we 
used the same magnification in the same field of view in the 
same section for many of the studies (Figure 9F). 
The CD31 and D2-40 immunoreactivities were more 
negative and less circumferential in the vessels contain-
ing tumor emboli. The same pattern of differences in the 
other lymphatic markers, eg., Prox-1 and VEGFR-3 in the 
normal lymphatics (Figure 9G, Figure 9H) versus the lym-
phatics containing tumor emboli (Figure 9I) was observed 
with  both  Prox-1  and  VEGFR-3  similarly  more  nega-
tive and less circumferential in the lymphatics containing 
tumor emboli (p=0.01) (p=0.01). Whereas single p63, dual 
p63/CD31 and dual p63/D2-40 immunoreactivities were 
completely absent in normal vessels, in occasional CD31 
immunostained, D2-40 immunostained or non-immunore-
active lymphatic channels containing tumor emboli, either 
single p63 myoepithelial immunoreactivity or dual myo-
epithelial and endothelial immunoreactivities were pres-
ent (p=.05) (Figure 10A; Figure 10B; Figure 10C) (Table 
3). Furthermore the dual immunoreactivities of p63/CD31 
and p63/D2-40 were present within the same cells (Figure 
10B; Figure 10C). In studies using single CD31 and D2-40 
immunoreactivities, it was clear that CD31 recognized both 
blood vessels as well as lymphatics. However in the double 
Figure 9. Additional immunocytochemistry of human breast 
carcinoma cases. (A) Myoepithelial p63 immunoreactivity (brown) 
within normal ducts in the breast cancer sections. (B) Myoepithelial 
p63 immunoreactivity (brown) in DCIS and CD31 immunoreactivity 
(red) in adjacent lymphovascular spaces. (C)  Myoepithelial p63 
immunoreactivity (brown) in DCIS. (D) Double immunohistochemi-
cal immunoreactivity of D2-40 lymphatics (brown) and CD31 blood 
vessels  (red).  (E)  CD31  immunoreactivity  (red)  in  a  lymphatic 
channel containing a tumor embolus. (F) CD31 and D2-40 nega-
tive immunoreactivities in two lymphovascular channels contain-
ing emboli and adjacent CD31 positive blood vessels (red). (G) 
Nuclear Prox-1 immunoreactivity (brown) within endothelial cells’ 
lining of normal lymphatic channels. (H) Cytoplasmic/membrane 
VEGFR-3 immunoreactivity (red) within endothelial cells’ lining of 
normal lymphatic channels. (I) VEGFR-3 immunoreactivity (red) in 
lymphatic channels containing tumor emboli. 
Figure 8. ImageJ algorithm (A) The ImageJ (National Institutes 
of  Health,  http://rsb.info.nih.gov/ij/)  was  used  to  “trace  and 
measure” the perimeter of images of DCIS. 100 such profiles in 
10 cases were captured. Other standard imaging algorithms were 
used to measure the elongation ratio and quantitate shape.  (B) A 
similar number of lymphovascular tumor emboli were traced and 
measured. (C) The probability density function using a Gaussian 
kernel and the size distribution of the DCIS clusters versus tumor 
lymphatic emboli. 
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immunocytochemical experiments, by using D2-40 as the 
first antibody and colorimetrically developing its target to 
brown before applying the second primary antibody, CD31, 
more effective discrimination between blood vessels and 
lymphatics could be achieved. Using both single as well as 
double immunostaining methods with CD31/D2-40, it was 
clear that the lymphovascular tumor emboli which were 
observed  juxtaposed  to  DCIS  were  mainly  within  lym-
phatic channels. This was confirmed in both the Prox-1 as 
well as the VEGFR-3 immunocytochemical studies. 
There was not much heterogeneity in the intensities of 
immunoreactivity exhibited by the cells positive for p63, 
CD31, D2-40, Prox-1 and VEGFR-3. The differences in 
these markers occurred with respect to their presence or 
absence  and  their  degree  of  circumferential  immunore-
activity.  Some  vascular  structures  and  ducts  showed  no 
circumferential  immunoreactivity,  some  showed  partial 
(≤50%), which meant that less than or equal to one half of 
the circumference of the duct or vessel exhibited staining 
and some showed greater than 50% circumferential stain-
ing. The best way to record these patterns was semiquan-
titative. 100 sections of each structure were analyzed and 
results expressed as the percentage exhibiting 0% immu-
noreactivity (no staining), less than or equal to 50% cir-
cumferential staining or greater than 50% circumferential 
immunostaining. We did not count positive cells per se nor 
the intensity of staining. “Normal” refers to normal ducts or 
vessels present within the breast carcinoma tissue sections 
(Table 3).  
The single p63 or dual p63/D2-40 and p63/CD31 immu-
noreactivities in occasional lymphatic channels containing 
tumor emboli and the more negative immunoreactivities 
of D2-40/CD31/Prox-1/VEGFR-3 in the majority of ves-
sels containing tumor emboli suggested the possibility that 
they represented immature and newly created vasculature 
derived from myoepithelial-lined ducts. In these dual label-
ing studies, we considered using fluorescently tagged sec-
ondary antibodies instead of HRP-conjugated antibodies. 
However it would be technically difficult to carry out these 
latter experiments because of the high amount of autofluo-
rescence present within paraffin-embedded archival mate-
rial. If we had the opportunity to work with fresh or fresh 
frozen tissues, a fluorescent approach would, in fact, be 
both feasible and desirable. 
Collectively the experimental as well as the observa-
tional studies suggested to us that the tumor emboli may 
have been the result of encircling lymphovasculogenesis 
rather than conventional lymphovascular invasion (Figure 
11). 
DISCUSSION
Emerging experimental and clinical evidence has sug-
gested that metastasis may be an earlier event in cancer 
progression than previously realized. Experimental stud-
ies in transgenic mice have observed the presence of breast 
cancer cells in the bone marrow even at the stage of atypi-
cal ductal hyperplasia or DCIS within the breast [1]. In 
observational  studies  in  humans,  both  circulating  tumor 
cells (CTCs) and disseminated tumor cells (DTCs) in the 
axillary lymph nodes and bone marrow have been noted in 
early stage disease, even at the stage of in situ carcinoma 
[28,29].
Observations  made  in  experimental  model  systems 
should be validated in actual human tumors, if possible, in 
order to strengthen the relevance of the findings to humans. 
Observations  such  as  epithelial-mesenchymal  transition 
(EMT),  autophagy,  emergence  of  the  multidrug  resis-
tance phenotype and vasculogenic mimicry are examples 
of important phenomena of tumor progression observed 
experimentally but only with modest confirmatory support 
in human cancers [15]. The findings of early metastasis in 
the experimental studies have begun to see some valida-
tions in the human situation. However more validations are 
certainly required. In the present study our experimental 
findings suggest cancer clusters can stimulate human myo-
epithelial cells or murine embryonal fibroblasts to engage 
in encircling lymphovasculogenesis which allows the clus-
ters to become lymphovascular emboli. Our observational 
Figure 10: Double immunocytochemistry of human breast car-
cinoma cases (A) p63 nuclear immunoreactivity (brown) (arrows) 
in the lining cells of a tumor embolus-containing lymphatic channel.
(B)  Dual  p63  nuclear  (brown)  (arrows)  and  CD31  membranous 
(red) immunoreactivities in a tumor embolus-containing lymphatic 
channel. (C) Dual p63 nuclear (brown) (arrows) and D2-40 mem-
brane (red) immunoreactivities in a tumor embolus-containing lym-
phatic channel. 
Figure  11.  Schematic  of  encircling  lymphovasculogenesis. 
Schematic depicts encircling lymphovasculogenesis that results in 
tumor emboli formation. 
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findings suggest that, in fact, in situ carcinomas can directly 
become lymphovascular tumor emboli. Both findings sup-
port the conclusion that early metastasis can occur in both 
an experimental animal model system as well as in humans.
Our hypothesis is that mammary myoepithelial cells or 
myoepithelial stem cells committed to the myoepithelial or 
fibroblast lineage transform to either endothelial cells or a 
commitment to the endothelial lineage. Our hypothesis to 
explain the genesis of tumoral emboli within lymphovas-
cular channels is to consider the possibility that myoepi-
thelial cells which surround clusters of DCIS, or stromal 
stem cells which lie adjacent to clusters of invasive carci-
noma might, under the right circumstances, transform into 
encircling endothelial cells, causing the clumps of in situ or 
invasive carcinoma cells to become tumoral emboli. 
In the experimental studies, the gross pattern of fluores-
cence observed in the collective experiments supported the 
conclusions that the unlabeled tumoral spheroids initially 
stimulated the growth of the labeled HMS-1 and MEFs 
which subsequently stimulated the influx of host cells within 
the tumoral extracellular matrix. On IHC examination the 
presence of GFP/RFP immunoreactivity within the cells 
which lined these lymphovascular channels containing the 
tumoral emboli supported our conclusions that the tumor 
cell clusters were inducing encircling lymphovasculogen-
esis from the injected HMS-1 or MEFs. This encircling 
lymphovasculogenesis  eventually  formed  communicat-
ing anastomoses with murine vessels. This is why hybrid 
fluorescence emerged in the GFP-transgenics injected with 
unlabeled  tumor  cells  and  RFP-labeled  HMS-1  cells  or 
MEFs. We did not observe fluorescence or encircling GFP/
RFP  immunoreactivity  when  the  HDFs  were  coinjected 
with the unlabelled spheroids. We interpret these findings 
to indicate that myoepithelial to endothelial or embryonal 
fibroblast to endothelial transformation may be mediated 
by stem/progenitor cells present in either the HMS-1 or the 
MEFs populations capable of pluripotency and the abil-
ity to switch to endothelial differentiation. It would not be 
unanticipated that an embryonal line like MEFs or a benign 
myoepithelial tumor cell line like HMS-1 would contain 
such pluripotent stem/progenitor cells. On the other hand, 
mature adult fibroblasts such as HDFs might lack such plu-
ripotent cells and be incapable of encircling lymphovascu-
logenesis or a switch in differentiation. 
In  the  mouse  studies,  the  coinjected  RFP-labeled 
HMS-1 or MEFs will always emit a red color and hence in 
the setting of the GFP-transgenics, the presence of anato-
mizing vessels is suggested by a yellow hybrid color. These 
experiments alone do not necessarily mean that the myo-
epithelial cells and embryonal fibroblasts developed into 
cells which lined the lymphovascular channels but taken 
together with the in vitro studies (Figure 4) and the other 
set of mouse studies showing GFP immunoreactivity in the 
cells lining the spaces (Figure 3), the aggregate studies sug-
gested this possibility. The yellow hybrid color observed 
in the murine studies would not further transition into a
green color because there would always be a combination 
of RFP-labeled HMS-1 or RFP-labeled MEFs and murine 
GFP-labeled endothelial cells or endothelial precursors in 
the tumor microenvironment giving the hybrid yellow fluo-
rescence.
Even though our experimental model utilized spheroids 
or clumps of invasive breast cancer cells and not true DCIS, 
when coinjected or cocultured with human myoepithelial 
cells, the myoepithelial cells encircled the spheroids both 
in vitro as well as in mice in the manner in which myoepi-
thelial cells lie juxtaposed to DCIS in vivo. When the spher-
oids were coinjected or cocultured with murine embryonal 
fibroblasts, these latter cells similarly encircled the spher-
oids both in vitro as well as in mice in the manner in which 
stromal fibroblasts lie juxtaposed to invasive ductal carci-
noma. Both the human myoepithelial cells and the murine 
embryonal fibroblasts developed into cells which lined the 
lymphovascular channels containing the tumor emboli. In 
both situations then, the carcinoma cells induced an encir-
cling lymphovasculogenesis.
It would be interesting if we could directly show that 
the presumed new lymphovascular structures transported 
fluid or cells. However, direct evidence for the above would 
require extensive imaging studies beyond the scope of the 
present study. However we believe that we have indirect 
evidence to support the above conclusions. The new lym-
phovascular structures labeled with GFP contained luminal 
erythrocytes indicating that they were transporting circulat-
ing red blood cells (Figure 3B). Furthermore murine studies 
with coinjected MARY-X spheroids and labeled HMS-1 or 
MEFs exhibited spontaneous pulmonary metastasis which 
could onlyoccur if the newly created lymphovascular stru-
ctures were able to communicate with the resident lympho-
vasculature and transport both fluid as well as tumor cells. 
We are not claiming in this study that the MARY-X 
model was a model of DCIS. Breast carcinomatous emboli 
are indeed invasive carcinoma and it is our hypothesis that 
they may gain access to lymphovascular channels by stim-
ulating the growth of the latter around them. To show this, 
we used a model of invasive carcinoma, MARY-X, that pos-
sessed the phenotype of florid lymphovascular invasion. In 
terms of the experimental model, the induction of lympho-
vasculogenesis takes origin from either murine embryonal 
stem cells (MEFs) or human myoepithelial cells (HMS-1) 
within the tumor microenvironment. In the observational 
studies we used cases in which DCIS was seen juxtaposed 
to areas of lymphovascular invasion without intervening 
stromal invasion. In both the murine experimental studies 
as well as the human observational studies, the common 
phenomenon of the induction of encircling lymphovascu-
logenesis is illustrated. But in the experimental studies it 
is invasive carcinoma doing the induction. In the observa-
tional studies it is the DCIS.
In the observational studies, we noted that in situ car-
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cinoma lay juxtaposed to LVI without intervening stromal 
invasion in 10 cases. Even after an exhaustive search for 
stromal invasion, we could not demonstrate it. Four pos-
sible explanations might still be considered to support stro-
mal invasion as being the mechanism of lymphovascular 
invasion in these 10 cases despite our not being able to 
demonstrate it: a) stromal invasion might have occured a 
long time before the tissue was sectioned; b) evidence for 
stromal invasion might be present in an adjacent piece of 
tissue that was not subjected to sectioning;  c) a very small 
number of tissues was analyzed in the present studies; d) 
one can not draw positive conclusions based on negative 
evidence. However in response to these considerations: a) 
the vast majority of human breast cancers show obvious 
and florid stromal invasion with lymphovascular invasion 
being rare. In these cases, the stromal invasion remains and 
does not disappear as the tumor grows. The proposed reason 
of why the stromal invasion is absent in our 10 cases was 
that it once was there and has now disappeared. This possi-
bility is just not tenable; b) exhaustive sectioning was done 
and certainly much more than the routine degree of section-
ing which is done in pathological analysis. If you applied 
this possible consideration to all of diagnostic pathology, 
you could argue that disease processes, like cancer, are rou-
tinely missed because their presence falls outside the area 
of sectioning. Although this can rarely occur, it certainly 
does not commonly occur or otherwise diagnostic pathol-
ogy would be completely unreliable. In the 10 cases of the 
present study, a deliberate and intense search for areas of 
stromal invasion was carried out. We sectioned all areas 
of the cancer (outside, midzone and inside) and failed to 
find stromal invasion; c) we have analyzed 10 cases to date 
in which we have observed this phenomenon. Although 
this may be perceived as a small number, we believe it 
to be a significant number because it is these exceptions 
that can prove the rule. In other words in the typical case 
of infiltrating breast cancer, the phenomenon of encircl-
ing lymphovasculogenesis may also be occuring but it is 
not possible to prove because of the presence of stromal 
invasion juxtaposed to lymphovascular invasion. In these 
typical cases,  one  has  to  presume  that  stromal  invasion 
progresses to lymphovascular invasion. However in the 10 
cases where there is the absence of stromal invasion but the 
presence of lymphovascular invasion, this presumption can 
be excluded and one is left with support for our hypoth-
esis: encircling lymphovasculogenesis;  d) Although it is 
true that absence of proof is not absolute proof of absence, 
we are not drawing positive conclusions solely on the basis 
of negative evidence. We have positive evidence: the pres-
ence of clusters of DCIS juxtaposed to clusters of tumoral 
emboli within lymphovascular spaces. Both clusters show 
similar  size,  proliferation  and  immunocytochemical  fea-
tures. That is circumstantial but positive evidence. It is the 
totality of evidence, both positive as well as negative, that 
supports our conclusions. 
Furthermore lymphatic markers, eg., D2-40, VEGFR-3, 
Prox-1 were completely absent in normal ducts as well as 
ducts containing DCIS. Therefore we believe that we have 
excluded the possibility that lymphatic markers are being 
expressed by a subset of myoepithelial cells that represent 
ducts containing DCIS rather than lymphatics containing 
tumor emboli. 
There was also no evidence for iatrogenic seeding. We 
reasoned that the only tenable hypothesis that would sup-
port these findings was one of induced encircling lympho-
vasculogenesis. In all 10 cases (Table 1), the morphometric 
and immunohistochemical evidence supported our hypoth-
esis. It is important to note that the vast majority of DCIS 
in patients does not manifest LVI in the absence of stromal 
invasion. Most DCIS, when associated with progression, 
exhibits frank stromal invasion. LVI occurs after there is 
significant stromal invasion. But the findings of our pres-
ent study indicate that this usual type of progression need 
not be canonical---that in situ carcinomas may progress to 
lymphovascular tumor emboli through an alternate “non-
invasive” mechanism. 
Because  it  could  also  be  argued  that  the  apparent 
tumoral emboli within lymphovascular spaces might, alter-
natively, be DCIS with separation artifact and a reduced or 
lost myoepithelial layer, we had to also consider this possi-
bility. We do not believe that we are observing a retraction 
artifact phenomenon here. First of all, retraction artifact is 
usually observed in islands of invasive ductal carcinoma 
and not DCIS. Secondly, the DCIS clusters which were 
obvious  were  surrounded  by  p63  positive  myoepithelial 
cells with no obvious separation artifact. The lymphovas-
cular tumoral emboli were surrounded by CD31 and D2-40 
positive endothelial cells. Thirdly the 10 cases of DCIS 
with LVI had metastases to axillary lymph nodes (Table 1). 
These findings all suggested that the LVI is true and not 
retraction artifact around DCIS, the latter of which would 
not give rise to axillary metastasis. 
Our  morphometric  and  tumoral  IHC  studies  (Table 
2)  indicated  no  differences  in  immunoreactivity  or  size 
(perimeter)  between  the  in  situ  clusters  and  the  tumor 
emboli (p=0.5) (p=0.1). This suggested that these struc-
tures were one and the same and remained intact during 
their in situ to LVI transition. 
With  respect  to  this  transition,  the  near  identity  of 
proliferation  (Ki-67)  and  immunocytochemical  adhesion 
markers (E-cadherin) further supported the hypothesis that 
these two structures were, in fact, related.  If the structures 
were not related, that is if the DCIS occurred independently 
and the lymphovascular emboli were derived from inva-
sive cells, it would be more likely that these markers within 
the emboli would change. Invasion is thought to involve 
epithelial-mesenchymal transition where there is loss of 
E-cadherin.  Furthermore  there  is  generally  thought  in 
tumor progression that there is clonal selection for a more 
aggressive phenotype with increased proliferation. It would 
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then be expected that if the lymphovascular emboli were 
derived from stromal invasion, that their E-cadherin would 
be decreased and their Ki-67 would be increased compared 
to the DCIS foci. On the other hand, if the DCIS clusters and 
lymphovascular emboli were one and the same, it would be 
expected that E-cadherin and Ki-67 would be nearly iden-
tical between the two structures and that is exactly what 
was observed. Slightly different morphometric differences 
in  shape  between  these  structures,  however,  would  not 
negate their identity of origin because the lymphovascular 
tumor emboli would likely be subjected to hydrostatic pres-
sures of lymph and blood flow that could easily alter their 
shape. Our collective histological and immunocytochemi-
cal findings, though not proving our hypothesis, support it. 
Although there are alternative explanations, the one that is 
most consistent with Occam’s razor is in situ – LVI transi-
tion.
Our hypothesis to explain the genesis of tumoral emboli 
within  lymphovascular  channels  then  is  to  consider  the 
possibility that myoepithelial cells which surround clusters 
of DCIS or stromal cells which lie adjacent to clusters of 
invasive carcinoma might, under the right circumstances, 
transform  into  encircling  endothelial  cells,  causing  the 
clumps of carcinoma cells to become tumoral emboli. If 
one  invoked  the  canonical  hypothesis  of  invasion  into 
pre-existing lymphatics and blood vessels to explain LVI, 
one would expect to see similarities in immunoreactivity 
between vessels containing and devoid of emboli since all 
of these vessels would have antedated the LVI. But our 
study observed CD31, D2-40, VEGFR-3 and Prox-1 dif-
ferences in the embolic channels. Newly derived vascular 
channels would be expected to be immature and express 
endothelial markers, podoplanin (D2-40), VEGFR-3 and 
PECAM-1  (CD31),  to  a  lesser  degree  than  mature  pre-
existing vessels (Table 3).  If one invoked the invasion 
hypothesis to explain LVI, p63 immunoreactivity would be 
decreased in the DCIS-surrounding myoepithelial layer but 
not persistent within the CD31 and D2-40 lymphovascular 
spaces containing emboli. Our myoepithelial and endothe-
lial IHC studies then also supported the concept of encircl-
ing lymphovasculogenesis. 
If we limited our studies to the use of a single endo-
thelial marker, we would have had to be more tentative in 
our conclusions. The use of single markers would limit the 
significance of our conclusions because in the tumor micro-
environment slight changes might occur in the expression 
of a single gene, without implying any significance. While 
we did not exhaustively examine the expression of every 
known endothelial marker, in our experimental studies we 
studied the induction of VEGFR-1, VEGFR-2, VEGFR-3, 
CD31 and podoplanin, five different endothelial markers. 
In our human studies we studied the endothelial immuno-
reactivites for four markers, CD31, D2-40, VEGFR-3 and 
Prox-1. Random co-expression of several endothelial mark-
ers is unlikely and for this reason, we believe that our data 
supports our hypothesis. Nevertheless our findings could 
have been strengthened by the use of additional markers 
of lymphatic endothelium including neuropilin-2, FOXC2, 
CCR7, CCL19, CCL21 and the mannose receptor. 
With these findings and this reasoning as background, 
we also observed lymphovasular channels with dual immu-
noreactivity.  These  channels  showed  CD31  and  D2-40 
immunoreactivities (red) as well focal p63 nuclear immu-
noreactivity (brown) (Figure 10). The focal brown nuclear 
immunoreactivity  can  be  contrasted  with  adjacent  non-
immunoreactive blue endothelial and tumoral nuclei pres-
ent within the same section. The use of confocal microscopy 
with  immunofluorescent  staining  would  be  theoretically 
helpful in confirming these findings, but because this was a 
retrospective study using paraffin-embedded archival path-
ological materials, the degree of autofluorescence would 
confound meaningful interpretation of confocal immuno-
fluorescent studies. We therefore, were not able to use this 
additional approach.
It had been known that myoepithelial cells exert tumor 
suppressive effects on DCIS [30-32]. More recently it had 
been demonstrated that myoepithelial cells can be para-
crinely regulated by DCIS [33-38] and undergo alterations 
in gene expression, and promoter methylation [35,36]. In 
these studies the findings suggested that myoepithelial cells 
can become less differentiated and manifest aberrant gene 
expression  including  expression  of  endothelial-related 
genes [2,7,36,39,40,41]. In our in vitro experimental stud-
ies of the induction of endothelial differentiation within the 
myoepithelial cells, we observed an increase in podoplanin 
(the antigen recognized by D2-40), VEGFR-3, VEGFR-
1, VEGFR-2 and CD31 transcripts over time when myo-
epithelial cells were cocultured with MARY-X spheroids. 
These studies suggest that endothelial (both lymphatic as 
well as vascular) proteins increase as the commitment to 
the endothelial lineage is made.  Interestingly, we tested 
MARY-X for all the VEGF growth factors by real time 
PCR and it expressed relatively higher levels of VEGF-C 
and VEGF-D than VEGF-A and VEGF-B compared to a 
number of common ER positive and ER negative breast 
cancer cell lines. MARY-X would be expected therefore to 
stimulate lymphangiogenesis. Still the other breast carci-
noma lines were not able to increase VEGFR-3, CD31 or 
podoplanin transcripts in HMS-1 cells, yet, in at least some 
of these other cell lines, VEGF-C transcripts were increased 
and presumbably VEGF-C was produced. The mechanism 
of induction of endothelial differentiation in myoepithelial 
cells may not therefore be mediated by the classic effectors 
of lymphangiogenesis, eg., VEGF-C. 
We believe that we have provided supportive evidence 
for the acquisition of the lymphatic phenotype by myoepi-
thelial cells in vitro. In the studies depicted in Figure 5, we 
examined the levels by RT-PCR of a number of endothelial 
markers in HMS-1 cells cocultured in media with MARY-X 
spheroids. At time 0, the expression of five different endo-
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thelial markers: VEGFR-1, VEGFR-2, VEGFR-3, CD31 
and podoplanin was very low but each increased to various 
degrees  when  cocultured  with  MARY-X  spheroids. The 
lymphatic endothelial markers, VEGFR-3 and podoplanin 
and the general endothelial marker, CD31 increased the 
most. We examined the presence of endothelial growth fac-
tors in MARY-X and compared the levels to other breast 
carcinoma lines and found that MARY-X makes high levels 
of VEGF-C. We did not measure the levels of VEGFR 
in MARY-X because this was not central to the present 
hypothesis and because in our analysis of the HMS-1 cells, 
there was no possibility of contamination by MARY-X. 
HMS-1 cells grew as a monolayer and the MARY-X spher-
oids grew in suspension without the ability to attach and 
the  two  cell  lines  are  easily  separated  from  each  other. 
Furthermore at time 0 (Figure 5B), levels of VEGFR and 
other endothelial markers were low in HMS-1 cells and 
increased over time. This increase could only occur if there 
was an induction of endothelial differentiation of HMS-1 
cells by the MARY-X spheroids. The rationale for studying 
the expression of VEGF in MARY-X is that we wanted to 
know what is different in MARY-X that might be respon-
sible for its unique ability to induce encircling lymphovas-
culogenesis and possible candidates would include VEGF 
family members. VEGF-C, despite some conflicting data, 
represents an attractive candidate for future studies. 
In  the  experimental  models  where  induced  vasculo-
genesis and / or vasculogenic mimicry has been observed 
[15-21],  the  phenomenon  facilitates  metastasis  from  the 
standpoint  that  the  vascular  channels  which  are  created 
anastomose with the resident vasculature. We can not tell in 
our observational studies whether anastomoses are occur-
ing as we can not see three dimensions in two dimensional 
sections.
Though  the  lymphovascular  tumor  emboli  were  of 
similar  size  as  the  in  situ  carcinoma  clusters  (Table  2), 
the lymphovascular channels containing the tumor emboli 
exhibited  evidence  of  immaturity  (Table  3).  Channels 
derived from encircling lymphovasculogenesis would be 
expected to be immature. We can not directly validate or 
investigate this assumption, however, in our observational 
studies. However in our experimental in vitro induction 
studies  of  endothelial  differentiation  of  myoepithelial 
cells,  we  observed  an  increase  in  podoplanin,  VEGFR-
3, VEGFR-1, VEGFR-2 and CD31 transcripts over time. 
These studies suggest that endothelial (both lymphatic as 
well as vascular) proteins increase as the commitment to 
the endothelial lineage is made during encircling lympho-
vasculogenesis.  
In a recent study which observed strong correlation of 
extensive retraction artifact in the primary carcinomas with 
nodal metastases, it was postulated that the retraction arti-
fact seen around tumor nests might be an early stage of 
LVI, where the conversion of mesenchymal cells to endo-
thelial cells had not yet occurred [42]. Retraction artifact 
may also then be a reflection of early encircling lympho-
vasculogenesis.  
Finally, it is known that “pure” DCIS can be associ-
ated with nodal metastases and explanations for this phe-
nomenon have been proposed ranging from sampling bias, 
microinvasion misinterpretation, iatrogenic dissemination 
and “revertant DCIS”, a phenomenon where DCIS reverted 
back from invasive carcinoma [43]. In light of the data pre-
sented in the present study one might propose yet another 
explanation --- encircling lymphovasculogenesis to explain 
how  initially  “pure”  DCIS  might  metastasize  without 
invading.
In both our experimental as well as observational stud-
ies, we have not shown that myoepithelial cells or embryo-
nal fibroblasts are capable of direct transdifferentiation into 
endothelial  cells.  Even  though  coinjection  experiments 
with HMS-1 and MEFs in mice suggested that they can 
form lymphovascular channels via encircling lymphovas-
culogenesis and that immunocytochemical observations in 
human cases indicated p63 nuclear/CD31 membrane and 
p63/D2-40 dual immunoreactivities within the same lining 
cell, stem cells within HMS-1 or MEFs or within the breast 
undergoing a switch in differentiation from myoepithelial 
or fibroblast to endothelial could account for our findings. 
We certainly do not know the mechanism for the induc-
tion  of  this  encircling  lymphovasculogenesis  observed 
experimentally in vitro or in mice or in the in situ–LVI 
cases. The resemblance of the in situ carcinoma clusters, 
the lymphovascular tumor emboli and the spheroids to the 
embryonal blastocyst raises the possibility that embryonic 
lymphovasculogenic signaling pathways may be involved. 
Our findings acknowledge the general importance of 
endothelial progenitor cells to tumor lymphovasculogen-
esis. Recent evidence, for example, has argued that some 
endothelial progenitor cells can reside in the bone marrow 
[20]. All endothelial cells do not need to take origin from 
pre-existing  endothelial  or  endothelial  precursor  cells, 
however. And not every case of human cancer need involve 
active lymphangiogenesis [44,45]. But what we are argu-
ing in this study is that active lymphovasculogenesis can 
occur and when it occurs, can occur from mesenchymal or 
myoepithelial precursors. 
In these experimental studies we used MARY-X. Since 
MARY-X represents an unusual type of breast cancer with 
a somewhat unique gene expression profile, cellular prop-
erties and behavior in vivo, one might question the general 
applicability of this model to other common forms of breast 
cancer.  If  one  focuses  on  the  lymphovascular  embolus, 
however, which is also present in non-IBC breast cancer, 
one might reason that the exaggerated phenotype of LVI 
exhibited by MARY-X provides a model to help under-
stand the phenomenon of LVI exhibited by common forms 
of breast cancer. 
Our use of the term “encircling lymphovasculogenesis” 
must  be  distinguished  from  “circumferential  lymphan-
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giogenesis”, which has been used to describe a different 
process [46]. This latter term refers to tumor-dependent 
induction  of  lymphangiogenesis  in  peritumoral  normal 
tissue surrounding the tumor mass. Our definition of the 
former term is the development of lymphovascular chan-
nels which envelop or encircle tumoral clumps creating 
lymphovascular tumoral emboli. The mechanisms behind 
“encircling  lymphovasculogenesis”  and  “circumferential 
lymphangiogenesis” may be similar, however. 
The  occurrence  of  encircling  lymphovasculogenesis 
does not negate, however, the generally accepted phenom-
enon of classic lymphovascular invasion which may still 
represent the usual and dominant route of metastasis. How-
ever this pathway of classic lymphovascular invasion need 
not be obligate. Alternate pathways such as  encircling lym-
phovasculogenesis may also be operating. 
Collectively our experimental as well as our observa-
tional studies suggest that breast cancer tumor emboli may 
result from encircling lymphovasculogenesis rather than 
conventional lymphovascular invasion. This phenomenon 
may help short-circuit some of the steps of the metastatic 
process which may indeed give rise to “early metastasis”. 
MATERIALS AND METHODS
Ethics Statement
This study was approved by The Ohio State University 
Cancer Institutional Review Board (IRB) under protocol 
2006C0042. All  animal  studies  and  in  vitro  experimen-
tal studies were approved specifically by The Ohio State 
University’s Animal Care and Use Committee (IACUC), 
protocol 2007A0218 and by The Ohio State University’s 
Institutional  Biosafety  Committee,  protocol  2007R0057. 
Use of human tissues was specifically approved by The 
Ohio State University Cancer Institutional Review Board 
(IRB) under protocol 2006C0042. 
Experimental studies
Cell lines. 
We used a previously established xenograft model of 
inflammatory human breast cancer (MARY-X), a model 
that exhibited a nodular growth pattern centrally and florid 
LVI peripherally and which generated tumoral spheroids 
in vitro. [22]. Inflammatory breast cancer is a unique type 
of breast cancer with a distinct genotypic and phenotypic 
profile [23-25]. The establishment of this xenograft model 
occurred in the 1990’s when the investigator was at the 
University of California at Los Angeles (UCLA) and was 
approved by the UCLA’s Institutional Review Board at that 
time. The human myoepithelial cells were obtained from 
a  previously  established  human  myoepithelial  cell  line 
(HMS-1) derived from a benign salivary gland tumor [26] 
also established in the 1990’s when the investigator was 
at UCLA and was also approved by UCLA’s Institutional 
Review Board at that time. The murine embryonal fibro-
blasts  (MEFs)  were  purchased  (American  Type  Culture 
Collection (ATCC), Manassas, VA) and adult human dermal 
fibroblasts (HDFs) derived from human adult skin, gifted 
by  Andrew  C.  Issekutz,  Dalhousie  University,  Halifax, 
Canada. All other lines consisted of the estrogen receptor 
(ER) negative breast cancer lines (MDA-MB-231, MDA-
MB-468), the ER positive line, MCF-7 and the Her-2/neu 
amplified breast cancer line,  HTB20, all also purchased 
(American  Type  Culture  Collection  (ATCC),  Manassas, 
VA).  All the cell lines were grown under standard con-
ditions in Dulbecco’s Modified Eagle Medium (DMEM) 
with 10% fetal bovine serum (FBS) with the exception of 
the fibroblast lines which were grown in Minimal Essen-
tial Medium (MEM)-alpha with 10% FBS and the myoepi-
thelial lines which were grown in keratinocyte serum free 
media (KSFM) with supplements (Life Technologies, Inc., 
Gaithersburg, MD). 
Transfections. 
A  retroviral  expression  vector  pLNCX2-DsRed  or 
pLNCX2-zsGreen containing enhanced green fluorescent 
protein (GFP) or red fluorescent protein (RFP) respectively 
was used to transfect a retroviral packaging cell line, Ret-
roPack PT67 (Clontech Laboratories, Inc., Mountain View, 
CA). The viral supernatants were harvested 72 hours after 
transfection. The filtered undiluted retroviral supernatants 
were used immediately to infect the target cells, HMS-1 
or MEFs which were seeded in 60-mm plates. After 48 hr, 
antibiotic G418 (500-1000 μg/ml) was added to select the 
clones. After 1-2 weeks, positive clones exhibiting intense 
fluorescence emerged and were monitored with the Fluo-
rescence  Imaging  Microscopy-Nikon  Eclipse  TE2000-U 
System. 
 We labeled both HMS-1 and MEFs with both GFP and 
RFP and conducted different combinations of experiments 
with these labeled lines. We chose two tags and two cell 
lines because we wanted to see both a single pattern of 
fluorescence in nude mice (using GFP-labeled HMS-1 or 
MEFs or RFP-labeled HMS-1 or MEFs) or a double pat-
tern of fluorescence in GFP-transgenic nudes (using RFP-
labeled HMS-1 or MEFs). We chose two cell lines because 
we  wanted  to  see  whether  either  human  myoepithelial 
cells, ie HMS-1 or murine embyonal fibroblasts, ie. MEFs 
could transform into endothelial cells when coinjected with 
MARY-X spheroids. We wanted to see whether encircling 
lymphovasculogenesis could be induced.
 
$QWLERGLHVDQGJHQHUDOUHDJHQWV
                 Two different monoclonal antibodies to human and murine 
           CD31 respectively included a rat monoclonal anti-human specific 
c         CD31 anti-body (PharMingen, San Diego, CA) and a rat monocl-
           onal anti-murine specificCD31 (PharMingen). A rabbit poly-
                                                                                                            clonal anti-vascular endothelial growth factor-3 (VEGFR-
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3)  (ab14828)  (Abcam,  Inc.,  Cambridge,  MA)  was  also 
obtained. Secondary antibodies included Texas Red conju-
gated goat anti-rat (Jackson ImmunoResearch Laboratory, 
West Grove, PA). and Texas red conjugated goat anti-rabbit 
(Sigma-Aldrich,  St.  Louis,  MO).  Primary  and  second-
ary antibodies were used according to the manufacturers’ 
recommendations. Matrigel matrix was obtained and used 
according  to  the  supplier’s  guidelines  (BD  Biosciences, 
Bedford, MA). 
Coculture experiments. 
Unlabelled  spheroids  generated  from  MARY-X  [22] 
were cocultured with either GFP-labeled HMS-1 or MEFs 
or unlabeled HMS-1 in monolayer culture or in Matrigel. 
Approximately equal volumes of each cellular population 
was added to this mixture. We used Matrigel in the in vitro 
experiments because we needed a three dimensional scaf-
fold to hold the MARY-X spheroids in place which would 
allow  the  cocultured  HMS-1  cells  or  MEFs  to  undergo 
chemotaxis  or  haplotaxis  toward  the  spheroids,  eventu-
ally encircling them. Without this Matrigel scaffold, this 
phenomenon could not occur as the monolayers of HMS-1 
and MEFs would not be able to reach the spheroids which 
would remain in suspension culture. In the Matrigel cocul-
tures involving HMS-1, anti-human specific CD31 antibody 
was added followed by Texas Red conjugated goat anti-rat. 
In  the  Matrigel  cocultures  involving  MEFs,  anti-murine 
specific CD31 antibody was added followed by Texas Red 
conjugated  goat  anti-rat.  The  Matrigel  cocultures  were 
observed over the next 24-96 hours by both phase contrast 
and  fluorescence  microscopy.  For  immunocytochemical 
staining, the cells of the Matrigel coculture were fixed in 
cold methanol: acetone (1:1) for 20 minutes. All the stain-
ing was carried out in blocking buffer. The stained cells 
were imaged on the Nikon Fluorescent microscope using 
the Roper camera and Metavue software (Universal Imag-
ing Corporation, West Chester, PA). 
In the monolayer coculture experiments with MARY-X 
spheroids in suspension and unlabeled HMS-1 cells as a 
monolayer, the spheroids which remained in suspension 
were separated from the monolayers of HMS-1 after 24, 
48, 72 and 96 hours. RNA was extracted from each cellular 
population obtained at these time intervals.
RNA Isolation and cDNA Synthesis. 
The total RNA was isolated from cultured cells or tis-
sues using RNeasy Mini Kit (Qiagen, Inc, Valencia, CA) 
per manufacturer's instructions. SuperScript III First-Strand 
Synthesis System (Invitrogen Corporation, Inc., Carlsbad, 
CA) was used for the first strand cDNA synthesis.
Real time PCR.
 An aliquot of 20 ng cDNA was used in each 25 µl PCR 
reaction, using Platinum Taq DNA Polymerase High fidel-
ity (Invitrogen Corporation, Inc.). The following conditions 
were used: denaturation at 94°C for 30 seconds, annealing 
at 58°C for 30 seconds, and extension at 68°C for 1 min for 
a total of 25, 30 or 35 cycles. PCR products were analyzed 
by 2.0% agarose gel. Real-time PCR was performed on a 
ABI 7500 Real-Time PCR System (Applied Biosystems, 
Inc., Foster City, CA). cDNA was combined with primer 
sets and Power SYBR® Green PCR Master Mix (Applied 
Biosystems, Inc) was used. Gene expression levels were 
calculated  relative  to  the  housekeeping  gene  β-actin  by 
using  7500  System  SDS  software  (Applied  Biosystems, 
Inc.).
  Primer sets (forward and reverse) used for real 
time PCR included the following (forward, reverse), all to 
human transcripts:


















 ACTB, 5'-GGCACCCAGCACAATGAAG-3', 
5'-GCCGATCCACACGGAGTACT-3'
Real time PCR experiments were repeated 5 times and 
results of relative mRNA levels depicted as mean ± stan-
dard deviation.
Animal experiments. 
Approximately  1x107  GFP-  or  RFP-labeled  HMS-1, 
MEFs or HDFs were mixed with the MARY-X spheroids 
on an equal volume basis and injected subcutaneously into 
nude mice (nu/nu mutants on a BALB/c background) or 
GFP-transgenic nude mice (Anticancer, Inc., San Diego, 
CA.) in groups of 10. In these murine experiments and 
the previously mentioned in vitro coculture experiments, 
the conditions for mixing HMS-1 or MEFs with MARY-X 
spheroids were expressed in volumes rather than cell num-
bers.  Because MARY-X forms spheroids which are very 
tight aggregates of tumor cells (approximately 103 in 100µ 
diameter spheroid) and we did not disadhere the spheroids 
into individual cells in our coculture or coinjection experi-
ments,  we  thought  it  more  accurate  to  express  relative 
amounts of cells added in volume rather than cell number 
terms. Furthermore the HMS-1 or MEFs are not in spher-
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oids but exist singly from a monolayer and they are made 
into a pellet whose density is much less than that of the 
spheroids. In both the in vitro as well as the murine experi-
ments, we mixed an equal volume of HMS-1 or MEFs with 
the MARY-X spheroids but because the MARY-X spher-
oids are at a much higher cell density there are approxi-
mately 20 fold more MARY-X cells than HMS-1 or MEFs 
in the same volume.
The injected mice were monitored for tumor growth by 
whole-body fluorescent imaging which was performed in 
a  fluorescent  light  box  (LT-9MACIMSYSPLUS  system) 
illuminated by fiber-optic lighting (LT-9PANSEE system) 
equipped with two 470/40nm excitation filters for dual flu-
orescent light (green and red) (Lightools Research, Encini-
tas, CA). At selected intervals ranging up to 2 months, the 
mice were euthanized with 25 mg/ml ketamine, 2 mg/ml 
xylazine  and  acepromazine  and  subjected  to  necropsy. 
Ertirpated tumors were processed for routine histological 
examination as well as IHC with rabbit anti-GFP and anti-
RFP polyclonal antibodies (BioVision Research Products, 
Inc., Mountain View, CA) followed by secondary antibody 
and DAB chromogenic detection.  
Observational studies
Selection and retrieval of cases. 
10 cases exhibiting DCIS with adjacent LVI but without 
stromal invasion were studied. The cases were exhaustively 
sectioned to exclude stromal invasion.  As controls, age-
matched and size-matched cases of DCIS, none of which 
exhibited LVI were selected for comparative studies.
Image Acquisition. 
The hematoxylin and eosin and immunocytochemical 
slides were scanned into virtual slides. Image acquisition 
utilized the Aperio ScanScope T2 scanner (Aperio, Vista, 
CA) producing images with a resolution of 20 pixels /10 µ.
 
Immunohistochemistry. 
The  immunohistochemistry  (IHC)  studies  utilized 
tumor  proliferation  (Ki-67)  and  adhesion  (E-cadherin) 
markers singly; and myoepithelial (p63) and lymphovascu-
lar (podoplanin [D2-40], CD31, Prox-1, VEGFR-3) mark-
ers both singly and in combination, the latter combination 
employing double immunohistochemical staining [27]. 
The primary antibodies used were as follows: Ki-67 
(clone MIB-1, Dako catalog number M7240), E-cadherin 
(clone NCH-38, Dako catalog number M3612), p63 (clone 
4A4, NeoMarkers, catalog number MS-1081-P1), D2-40 
(clone D2-40, Dako, catalog number M3619), VEGFR-3 
(ab14828)  (rabbit  polyclonal,  Abcam,  Inc.,  Cambridge, 
MA), Prox-1 (clone 5G10, Millipore, Inc., Billerica, MA) 
and  CD31  (rabbit  polyclonal,  catalog  number  E11114, 
Spring Bioscience,  Fremont, CA).
For the single immunostaining methods (Ki-67, E-cad-
herin, D2-40, CD31, VEGFR-3, Prox-1), the primary anti-
body was diluted 1:100 and incubated for 30 minutes at 
room temperature. For Ki-67, E-cadherin and D2-40, the 
detection system used was a labeled Streptavidin-Biotin 
Complex.  DAB  chromogen  was  applied  to  develop  the 
color. As controls for non-specific staining, we used nega-
tive isotype controls in all of our IHC experiments. For 
CD31 and VEGFR-3, the detection system, MACH 4 (Bio-
care Medical catalog M4U536L) was incubated for 30 min-
utes.  Vulcan Fast Red was used to develop the color.
We carried out double staining for a number of dif-
ferent  combinations  of  antibodies.  These  included  p63/
CD31,  p63/D2-40,  p63/VEGFR-3,  D2-40/CD31.  Prox-1 
was used in only the single immunostaining and not the 
double  immunostaining.  The  double  staining  procedure 
was always the same: The first antibody was used at the 
manufacturer’s suggested dilution. The detection system, 
used  was  envision  plus  dual  link  for  the  first  antibody 
(Dako code K4061). Lastly, DAB chromogen was applied 
to develop the signal of the first target. The second antibody 
was also used at the suggested manufacturer’s dilution. The 
detection system, MACH 4, was used for the second anti-
body. Vulcan Fast Red was used to develop the signal of 
the second target.
For p63/D2-40 and p63/VEGFR-3 double staining, the 
p63 antibody was used first at a dilution of 1:500 and incu-
bated for 30 minutes at room temperature.  The detection 
system, envision plus dual link (Dako code K4061) was 
incubated  for  30  minutes.  Lastly,  DAB  chromogen  was 
applied to develop the p63.  D2-40 or VEGFR-3 was used 
at a dilution of 1:200 and incubated for 30 minutes at room 
temperature. The detection system, MACH 4, was incu-
bated for 30 minutes. Vulcan Fast Red was used to develop 
either the D2-40 or the VEGFR-3 so that the two primary 
antibodies  recognizing  either  myoepithelial  or  lympho-
vascular differentiation could be easily differentiated. For 
the D2-40/CD31 double staining, the D2-40 antibody was 
used as the first antibody. This was so because while D2-40 
is thought to recognize lymphatics and not blood vessels, 
CD31 can recognize both lymphatics as well as blood ves-
sels. By using D2-40 as the first antibody and colorimetri-
cally developing its target to brown before applying the 
second primary antibody, CD31, more effective discrimi-
nation of lymphatics from blood vessels could be achieved.
 
Morphometric and Quantitative IHC Analysis. 
100 examples of each of the following were imaged 
and studied: ductal structures identified by circumferen-
tially positive p63 nuclear myoepithelial immunoreactivity, 
DCIS clusters identified by morphological criteria, and at 
least partially circumferential p63 immunoreactivity; blood 
vessels and /or lymphatics identified by positive circum-
ferential CD31 endothelial membrane immunoreactivity; 
lymphatics  identified  by  positive  circumferential  D2-40 
membrane  immunoreactivity,  Prox-1  nuclear  immunore-
Oncotarget 2010; 1: 131-147 www.impactjournals.com/oncotarget/145
activity  or VEGFR-3  cytoplasmic/membrane  immunore-
activity; tumor emboli within vascular channels identified 
by morphology and / or at least partially circumferential 
CD31, D2-40, VEGFR-3 or Prox-1 immunoreactivity. The 
degrees of tumoral E-cadherin and Ki-67 immunoreactivi-
ties were quantitated from the virtual slides. Similarly the 
presence of single p63, CD31, D2-40, VEGFR-3 or Prox-1 
or dual p63/D2-40, p63/CD31, p63/VEGFR-3 and D2-40/
CD31 immunoreactivities within the lining myoepithelium 
or endothelium was quantitated. ImageJ [National Institutes 
of Health, http://rsb.info.nih.gov/ij/] was used to measure 
the perimeters of DCIS clusters and tumor emboli captured 
from scanned slides. Other standard imaging algorithms 
were used to measure the elongation ratio (ratio of short to 
long axis) of the DCIS clusters and the tumor emboli. 
Statistics
Results of all in vitro and animal experiments and IHC 
measurements on the human tissue sections of the different 
groups (DCIS versus tumor emboli) were analyzed statisti-
cally with the two tailed Student’s t-test as well as with an 
Analysis of Variance. Univariate kernel density estimation 
was performed for each perimeter measurement (ducts and 
vessels). The univariate kernel density is a measure of size 
distribution and is a standard way used to compare the dis-
tributions of two apparently different populations, in this 
case ducts containing DCIS and vessels containing tumoral 
emboli to investigate the similarity or dissimilarity of these 
two populations. The univariate kernel density was sug-
gested to us by the Center for Biostatistics at Ohio State 
University.
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